Jonathan Silverberg, MD, PhD, MPH

025 Revolutionizing Atopic Dermatitis (RAD) Conference

 in Nashville, TN, a presentation titled ‘Recent Approvals in [Atopic Dermatitis] Therapy’ was given to attendees to highlight decisions in the atopic dermatitis space by the 

One presenter of this talk on recent atopic dermatitis approvals by the FDA was Jonathan Silverberg, MD, PhD, MPH, professor of dermatology and director of clinical research at the George Washington University School of Medicine and Health Science. Silverberg spoke with 

 in a new Q&A interview on this topic and on related research. The interview is listed below:

 In your talk ‘Recent Approvals in AD Therapy,’ what are some of the most notable takeaways regarding FDA approvals for atopic dermatitis covered in this session?

I just presented on recent atopic dermatitis approvals, particularly focusing on biologic and systemic therapies. We have 2 new therapies that were just approved in the past 12 months, which are nemolizumab and lebrikizumab as biologics. So I took a deep dive into both of those drugs and my own clinical pearls, as well as some thoughts about where and how to use them.

I also threw an update on data that we have now or recent data that we have for dupilumab as well as the oral JAK inhibitors, because we've had a lot of new insights, even though, technically, they're a little bit older therapies.

 With upcoming therapeutic research in atopic dermatitis, are there any drugs not approved yet which you are looking forward to?

Yeah, the pipeline for atopic dermatitis therapies is enormous right now, and it's really cool. There's a lot of stuff being tested with a lot of novel technologies. I think long-term, the bispecifics or multi-specific biologics are really cool. The ability to hit multiple targets simultaneously [is great], but without the off-target effects.

We're seeing all kinds of novel pathways being probed in atopic dermatitis, OX40 and 40 ligand, interleukin-18, interleukin-22 receptor. And we're not sure where all these are going to go. But these are really exciting and pushing the boundaries of science and the disease.

 Outside of atopic dermatitis, what are you looking forward to in terms of dermatology research?

I think there's a tremendous need, outside of atopic dermatitis and broadly-speaking within dermatology, for better diagnostics and better biomarkers. I think our classification system that we use in dermatology, while over 100 years old, and while we have great, skilled clinical dermatologists doing it, really needs to be brought into the modern era. We really need to have better prognostic tools, theranostic tools, and diagnostic tools across the variety of our different immune mediated diseases and just chronic inflammatory skin disorders.

You are the founder of RAD. What message would you share with colleagues, clinicians, and attendees?

 RAD was created to address this amazing increase in knowledge and treatment options that we have now for atopic dermatitis. It's hard for the clinician who's busy in the trenches to keep up with all the data and to really gain insights into all these new therapies that kind of hit us at once and are still coming really fast and furious.

How do we where should we use them? When should we use them? How do we keep up with all that? RAD is here to provide both cutting edge perspectives as well as that evidence-based approach, knowing that you're getting the top quality information all in a one-stop shop.

To find out more from Silverberg and other experts in the field of dermatology, view our 

The quotes used in this Q&A interview were edited for the purposes of clarity.

Articles

The 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville featured a presentation on recent FDA approvals in atopic dermatitis therapy, focusing on biologic and systemic treatments. Jonathan Silverberg, MD, PhD, MPH, highlighted new therapies, including nemolizumab and lebrikizumab, and discussed updates on dupilumab and oral JAK inhibitors. He emphasized the promising pipeline of novel therapies targeting multiple pathways. Silverberg also stressed the need for improved diagnostics and biomarkers in dermatology. RAD aims to provide clinicians with cutting-edge, evidence-based insights into emerging treatments.

In this Q&A interview, Silverberg highlighted takeaways from his talk at RAD 2025 on recent FDA approvals for atopic dermatitis.

Recent FDA Approvals for Atopic Dermatitis, with Jonathan Silverberg, MD, PhD, MPH

Emerging Treatments for Atopic Dermatitis

Video content above is prompted by the following:

Are there any ongoing atopic dermatitis studies or emerging therapies that you are excited about?

What advice would you like to share with clinicians taking care of patients with moderate/severe atopic dermatitis?

Videos

Recent advancements in atopic dermatitis research have focused on novel therapies and ongoing clinical trials. Emerging treatments, such as biologics and small molecules, are showing promise in managing moderate to severe cases. Clinicians are advised to stay informed about these developments to optimize patient care. Emphasizing a personalized approach, considering patient-specific factors, and maintaining open communication with patients are crucial. Additionally, integrating new therapies with existing treatment regimens can enhance outcomes. Continuous education and collaboration with specialists are essential for improving management strategies in atopic dermatitis.

Looking to the future of atopic dermatitis treatment, the panel discusses ongoing research and promising emerging therapies. 

Treatment of Bio-Naïve Patients or Those Progressing on Topical or Biologic Atopic Dermatitis Therapy

A bio naïve patient with moderate atopic dermatitis?

A patient whose disease is continuing to progress on topical treatments?

In managing atopic dermatitis, treatment strategies vary based on patient history and disease progression. For a bio-naïve patient with moderate atopic dermatitis, initial treatment typically involves topical therapies, including corticosteroids and calcineurin inhibitors. If the disease progresses despite topical treatments, systemic therapies or phototherapy may be considered. For patients not responding to biologic therapy, switching to an alternative biologic or incorporating adjunctive treatments may be necessary. Treatment plans should be individualized, considering patient-specific factors and potential side effects, to optimize therapeutic outcomes and improve quality of life.

Focusing on clinical scenarios, experts on atopic dermatitis discuss how their treatment approaches vary depending on patient-specific factors.

Use of JAK Inhibitors and Systemic Treatments for Atopic Dermatitis

How widely are clinicians using targeted agents that have become available over the last few years?

Where do you place JAKi vs biologics in the treatment of atopic dermatitis?

When during patient’s treatment journey would you recommend use of JAK inhibitors to your patients?

Who is an ideal candidate for JAKi use in atopic dermatitis?

The integration of targeted agents, including JAK inhibitors (JAKi), in clinical practice for atopic dermatitis has been increasing. Clinicians are evaluating the positioning of JAKi relative to biologics, considering factors such as efficacy, safety, and patient-specific characteristics. JAK inhibitors are often recommended for patients who have not responded adequately to topical treatments or biologics. Ideal candidates for JAKi are those with moderate to severe atopic dermatitis, particularly when rapid symptom control is needed or when other systemic therapies are contraindicated or ineffective.

Dermatologists outline the role of targeted therapies and JAK inhibitors in the treatment of patients with atopic dermatitis.